Background {#Sec1}
==========

Lung cancer is the most common malignant tumor and the dominant cause of cancer-related deaths in China \[[@CR1]\]. The 5-year overall survival rate of patients with lung cancer remains approximately 15%--18% even in developed countries \[[@CR2]\], whereas for patients who undergo surgical resection of stage I cancer this rate is well above 70% \[[@CR3]\], highlighting the urgent need for early detection and treatment. First introduced in the 1990s, low-dose computed tomography (CT) has become the most promising approach for lung cancer screening \[[@CR4]\]. Increasing number of screening programs in North America \[[@CR5]\], Japan \[[@CR6]\], and Europe \[[@CR7]--[@CR14]\] have greatly augmented the volume of the evidence base concerning low-dose CT screening practice. However, in China, a country with 36% of all lung cancers worldwide \[[@CR15]\], mortality outcome, which is the most important measure for assessing screening effects, has not yet been evaluated despite numerous preliminary studies on diagnostic accuracy \[[@CR16]\].

The United States National Lung Screening Trial (NLST) has reported an encouraging 20% reduction in lung cancer mortality with low-dose CT screening over chest X-ray screening \[[@CR5]\]. However, uncertainties remain regarding the mortality outcomes of screening programs because of controversial results from other countries \[[@CR7]--[@CR14]\]. Two randomized controlled trials (RCTs) from Italy \[[@CR7], [@CR8]\] and one from Denmark \[[@CR9]\] reported equal or slightly increased mortalities (not statistically significant) for low-dose CT screening compared with no screening. Five ongoing RCTs (from Germany \[[@CR10]\], Italy \[[@CR11]\], France \[[@CR12]\], the Netherlands, Belgium and Hungary \[[@CR13]\], and the United Kingdom \[[@CR14]\]) have not yet released their mortality outcomes. Outcomes of screening programs may vary between settings because of diversity in participants' characteristics and healthcare service conditions \[[@CR17]\]. Therefore, there is a need to investigate whether early detection by low-dose CT screening could reduce lung cancer mortality in China and to investigate the variations in screening effects before introducing such screening countrywide. This study aimed to analyze differences in lung cancer mortality between three scenarios using available data from China and to identify factors that most strongly influence the outcomes in low-dose CT screening.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

In this study, we simulated a cohort of 100,000 urban residents and offered them one-off lung cancer screening (baseline screening, i.e., prevalence screening). The age and sex structures of this cohort were based on data from the China Population & Employment Statistics Yearbook 2014 \[[@CR18]\]. According to data on lung cancer incidence reported by the National Cancer Registry 2012 \[[@CR19]\], age criterion for this cohort was set at 45--80 years. As there is currently no high-quality evidence-based recommendation on inclusion criteria for lung cancer screening in China \[[@CR20]\], we adopted the relatively relaxed criterion of "smokers" as a requirement of the 100,000 participants, regardless of daily smoking dose, smoking years, and cumulative pack-years (this choice of criterion was made also because it was used in national surveys on smoking in China \[[@CR21]\]). No other restrictions were imposed such as family history of lung cancer or individual history of pulmonary disease. However, we did exclude lung cancer screening for special categories, such as patients with tuberculosis or human immunodeficiency virus infection and individuals with work-place exposure to asbestos, coal dust, nuclear radiation, organic solvents, and fuels.

Decision tree model {#Sec4}
-------------------

Decision analysis is widely used to make choices between different paths in Chaotics and uncertain conditions \[[@CR22]\], especially in healthcare studies where medical outcomes such as mortality depend on a great number of potentially influencing factors \[[@CR23]\]. To identify the best approach to detecting lung cancer so as to improve outcomes and to test the degree of uncertainty, we considered and compared the following three possible paths for lung cancer detection and treatment (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Decision tree model for the analysis of lung cancer mortality, false positive diagnosis, and death due to false diagnosis with low-dose computed tomography (CT) screening and no screening. Chest X-ray screening is similar to low-dose CT screening and is not shown. *prev* lung cancer prevalence in the screened cohort, *CTse* sensitivity of low-dose CT, *CTsp* specificity of low-dose CT, *CTerl* proportion of early-stage cancers among lung cancers detected with low-dose CT, *NSerl* proportion of early-stage cancers among lung cancers detected with no screening, *fpMt* death possibility due to false diagnosis and invasive treatment, *trt_Er* acceptance rate of surgery for individuals with early-stage lung cancers, *trt_Ne* acceptance rate of surgery for individuals with non-early-stage lung cancers, *srv_Er* survival possibility of individuals with resected early-stage lung cancer, *CTidl* proportion of indolent cancers among lung cancers detected with low-dose CT, *srv_Ne* survival possibility of individuals with resected non-early-stage lung cancer

### Low-dose CT screening scenario {#Sec5}

Individuals with findings suggestive of lung cancer on low-dose CT images were asked to undergo further investigation, such as bronchoscopy and percutaneous biopsy, to determine the diagnosis and then either accept or refuse surgical treatment. Additionally, we set up branches in the path corresponding with "missed diagnosis" caused by false negative imaging results (merging into the no screening path described below), "false diagnosis" caused by false positive imaging results, and the "over diagnosis" issue (individuals with indolent cancer who live for a long time though untreated) recently raised by researchers \[[@CR24]\].

### Chest X-ray screening scenario {#Sec6}

The overall path was similar to that in the low-dose CT screening scenario, with the only difference being that the variables were adjusted to chest X-ray screening.

### No screening scenario {#Sec7}

Individuals with lung cancer detected and further diagnosed according to symptoms or medical examinations for other diseases took the usual health care treatment path.

All the three scenarios were stratified by early (stage I for non-small cell lung cancers and limited stage for small cell lung cancers) and non-early stage cancers, considering the impact of disease stage on the acceptance rate of surgery and survival possibility after surgery.

Additionally, the following assumptions were made for the decision tree. First, surgery is a determinant for lung cancer mortality (except for indolent cancers), and although non-surgical treatments could prolong patient survival, their small impact on the final outcomes was not taken into account \[[@CR25]\]. Second, a 5-year time span was adopted. As the screened cohort had a high competing risk from other diseases, deaths beyond the 5-year range were not considered in the outcome evaluation.

Parameter setting {#Sec8}
-----------------

Table [1](#Tab1){ref-type="table"} lists all the variables and the estimated values of parameters used in the decision tree. Specifically, the selection of screening parameters of low-dose CT and chest X-ray and the clinical parameters of diagnosis and treatment path were based on a systematic search of literatures (mainly from studies in China, together with a few studies in other countries, all extracted from MEDLINE, EMBASE, CNKI, and ChinaInfo databases and published between January 1990 and February 2016). Quality-weighted meta-analyses were performed to obtain the average estimate of parameter for each tree variable for base-case analysis (analysis based on the most likely estimates of parameters) and a reliable range for sensitivity analysis.Table 1Parameter settings in the decision tree for lung cancer screening in urban ChinaVariableDefinitionBase-case analysis (%)Sensitivity analysis (%)Reference sourceLower limitUpper limitprevLung cancer prevalence in the screened cohort0.76660.38330.8943Calculated from \[[@CR18], [@CR22], [@CR26], [@CR32], [@CR53]\]CTseSensitivity of low-dose CT87.771.8100.0Meta of \[[@CR21], [@CR54]--[@CR66]\]CTspSpecificity of low-dose CT90.686.391.1Meta of \[[@CR55], [@CR57]--[@CR60], [@CR63], [@CR66]--[@CR69]\]XRseSensitivity of chest X-ray65.161.469.4Meta of \[[@CR21], [@CR55]--[@CR57], [@CR60], [@CR62]--[@CR65], [@CR70]\]XRspSpecificity of chest X-ray97.589.598.4Meta of \[[@CR55], [@CR57], [@CR60], [@CR63], [@CR69], [@CR71], [@CR72]\]CTerlProportion of early-stage cancer^a^ among lung cancers detected with low-dose CT70.163.976.0\[[@CR73]\]XRerlProportion of early-stage cancer^a^ among lung cancers detected with chest X-ray46.638.155.0\[[@CR73], [@CR74]\]NSerlProportion of early-stage cancers^a^ among lung cancers detected with no screening27.923.232.7Meta of \[[@CR24], [@CR55], [@CR76]--[@CR79] [@CR52] ^d^, [@CR75] ^e^, \]CTidlProportion of indolent cancers^b^ among lung cancers detected with low-dose CT25.015.035.0\[[@CR20]\]XRidlProportion of indolent cancers^b^ among lung cancers detected with chest X-ray20.015.025.0\[[@CR20]\]trt_ErAcceptance rate of surgery for early-stage lung cancers^a^72.568.276.0Meta of \[[@CR80]--[@CR82]\]trt_NeAcceptance rate of surgery for non-early-stage lung cancers^a^28.628.230.6Meta of \[[@CR80]--[@CR82]\]srv_ErSurvival possibility of individuals with resected early-stage lung cancer^c^72.762.375.7Meta of \[[@CR3], [@CR35], [@CR83]\]srv_NeSurvival possibility of individuals with resected non-early-stage lung cancer^c^39.730.242.4Meta of \[[@CR3], [@CR35], [@CR83]\]fpMtDeath possibility due to false diagnosis and invasive treatment0.070.000.13\[[@CR84]\]*CT* computed tomography^a^Stage I for non-small cell lung cancers and limited stage for small cell lung cancers were defined as early-stage cancers, and others as non-early-stage cancers^b^Lung cancers such as bronchioloalveolar carcinoma that did not affect survival for a long time if left untreated were defined as indolent cancers^c^Based on 5-year estimation^d^Seven studies that were conducted among the Chinese population with complete stage information \[[@CR85]--[@CR91]\] in this meta-analysis were included and reanalyzed in this study^e^Eight studies with complete stage information \[[@CR92]--[@CR99]\] in this meta-analysis were included and reanalyzed in this study

Lung cancer prevalence of the screened cohort was calculated as follows.

First, age- and sex-specific lung cancer incidences in the general Chinese urban population ($\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$I_{\text{G}}$$\end{document}$) were extracted from the China Cancer Registry 2012 (urban data) at age intervals of 5 years \[[@CR19]\]. Next, the incidence of the screened cohort ($\documentclass[12pt]{minimal}
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                \begin{document}$$I_{\text{S}} = \frac{{{\text{OR}} \times I_{\text{G}} }}{{1 + ({\text{OR}} - 1) \times R}}$$\end{document}$$where *R* is the age- and sex-specific rate of smoking reported in the Global Adult Tobacco Survey (GATS) China 2010 Country Report \[[@CR26]\] and OR (2.85 for men and 2.33 for women) is the odds ratio according to meta-analysis results based on five case--control studies in China that used newly incident lung cancers to estimate the degree of association between smoking and lung cancer between 2001 and 2014 \[[@CR27]--[@CR31]\].

Further, because lung cancer prevalence is relatively stable in China, the following formula was used to calculate age- and sex-specific lung cancer prevalence in the screened cohort ($\documentclass[12pt]{minimal}
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                \begin{document}$$P_{\text{S}} = I_{\text{S}} \times t$$\end{document}$$where *t* = 3.0 years (sensitivity range 1.5--3.5 years) is the average course of lung cancer \[[@CR32]\].

Finally, the overall prevalence of lung cancer in the screened cohort aged 45--80 years was calculated by standardizing the age- and sex-specific prevalence using the actual demographical structure reported in the China Population & Employment Statistics Yearbook 2014 \[[@CR18]\] and the smoking rates in the GATS China 2010 Country Report \[[@CR26]\].

Quality-adjusted life year (QALY) \[[@CR33]\] was analyzed for the three scenarios over a 5-year time span. Quality utilities that were incorporated into the model were 0.76 for individuals without lung cancer \[[@CR34]\], 0.62 for the time from detection of lung cancer to surgical treatment \[[@CR35]\], 0.67 for early- and 0.55 for non-early-stage cancer patients after surgical treatment \[[@CR35]\], and 0.56 for those who refused surgical treatment after detection, regardless of cancer stage and presence of other treatments \[[@CR35]\]. We used an average delay of 0.5 years to lung cancer detection in the no screening scenario compared with the two screening scenarios, and incorporated an interval of 0.25 years for all the individuals with lung cancer from detection to surgical treatment (by expert consultation). The mean survival within the 5-year time span was estimated as 4.31 and 2.99 years for individuals with resected early- and non-early-stage cancers, respectively \[[@CR3]\], and as 2.78 and 0.71 years for individuals with non-resected early- and non-early-stage cancers, respectively \[[@CR36]\].

Additionally, to explore the influences of criteria of age, smoking, and sex on the prevalence of lung cancer in the screened cohort (and therefore on screening outcomes), with the same procedures described above, we further calculated different $\documentclass[12pt]{minimal}
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                \begin{document}$${\text{P}}_{S}$$\end{document}$ for men and women separately, each with 11 different proportions of smoking among the enrolled individuals if screening was not restricted to smokers.

Statistical analysis {#Sec9}
--------------------

Lung cancer death was the primary outcome measure in this study. Using base-case analysis, we calculated the absolute and relative reductions in lung cancer deaths with low-dose CT screening over chest X-ray screening and no screening. False diagnosis, death due to false diagnosis, and QALY as secondary outcome measures were simultaneously calculated and compared. Univariate sensitivity analysis (by separately letting each variable in the model fluctuate within its lower and upper ranges for sensitivity analysis while keeping the others at their base-case analysis values) was performed to investigate the influences of screening conditions on outcomes in different scenarios, and a tornado diagram was plotted to vividly display the magnitude of the influence of each variable (relative importance of the variables was ranked by percentages of variations in the outcomes due to their own influence over the variation summary due to influence of all variables). Optimal and worst cases of reductions in lung cancer deaths with low-dose CT screening over other scenarios were determined by considering combinations of all possible ranges of the variables. All the analyses were performed with Treeage Pro 2011 software (TreeAge Software, Inc, Williamstown, MA, USA).

Results {#Sec10}
=======

Base-case analysis {#Sec11}
------------------

Age and sex distribution of the simulated cohort in the base-case analysis is displayed in Table [2](#Tab2){ref-type="table"}. Among these 100,000 urban smokers (94,012 men and 5988 women) aged 45--80 years, 721 men and 46 women had lung cancers. As to the outcomes in the three scenarios for the same cohort, the number of lung cancer deaths in the low-dose CT screening scenario was 448, a reduction of 143 (24.2%) over the no screening scenario (591 lung cancer deaths); meanwhile, low-dose CT screening resulted in 9387 false diagnoses and 7 deaths due to false diagnosis. In the chest X-ray screening scenario, there were 541 lung cancer deaths, a reduction of 50 (8.5%) over the no screening scenario, and chest X-ray screening resulted in 2497 false diagnoses and 2 deaths due to false diagnosis. There were 93 fewer lung cancer deaths (17.2%) in the low-dose CT screening scenario than in the chest X-ray screening scenario; however, false diagnoses and deaths due to false diagnosis were 3.76 and 3.50 times higher, respectively, in the former scenario. Additionally, QALYs were 378,427 years in low-dose CT screening, 378,280 years in chest X-ray screening, and 378,177 years in no screening scenarios, that is, low-dose CT screening resulted in slightly more QALYs: 147 years over chest X-ray screening and 250 years over no screening.Table 2Age and sex distribution of the simulated smoking cohort for base-case analysisAge group (years)General population structure (%)^a^General population smoking rate (%)^b^No. of smokers for base-case analysis (total = 100,000)No. of lung cancer patients in 100,000 smokers for base-case analysisMenWomenMenWomenMenWomenMenWomen45--4913.412.669.52.929,489115764350--5410.19.463.14.120,307122488455--599.39.361.93.018,356884123560--646.87.154.92.511,793566126465--694.44.745.78.1640312001091370--743.23.542.3^c^4.3^c^4259476103875--802.93.436.7^c^4.5^c^34054811089Summary50.149.959.13.894,012598872146^a^Obtained from Sampling Survey Data of the National Population Change in 2013 in China Population & Employment Statistics Yearbook \[[@CR18]\]^b^Obtained from Global Adult Tobacco Survey (GATS) China 2010 Country Report \[[@CR26]\]^c^Predicted using linear regression

Univariate sensitivity analysis {#Sec12}
-------------------------------

Lung cancer prevalence in the screened cohort was the factor that most strongly influenced the death reduction with low-dose CT screening over no screening (Fig. [2](#Fig2){ref-type="fig"}). The variation in prevalence (from 383.3 to 894.3 per 100,000) led to a great variation in the absolute reduction in lung cancer deaths (from 68 to 168), being responsible for 61.3% of the all-variable influence. Other six factors besides the lung cancer prevalence contributed positively to the death reduction benefit in the following order: low-dose CT sensitivity (14.3% of the all-variable influence), proportion of early-stage cancers among lung cancers detected with low-dose CT (9.5%), survival possibility of individuals with resected early-stage lung cancer (4.7%), proportion of indolent cancers among lung cancers detected with low-dose CT (4.1%), acceptance rate of surgery for early-stage lung cancers (0.3%), and specificity of low-dose CT (0.1%). These six factors together contributed 33.0% to the variation in reduction in lung cancer deaths. Four factors were negatively related with reduction in lung cancer deaths with low-dose CT screening over no screening, namely proportion of early-stage cancers among lung cancers detected with no screening (4.3%), possibility of death due to false diagnosis and invasive treatment (0.9%), survival possibility of patients with resected non-early-stage lung cancer (0.6%), and acceptance rate of surgery for non-early-stage lung cancers (0.01%); however, their cumulative influence was subtle (5.8%).Fig. 2Tornado histogram of lung cancer deaths in the low-dose CT screening scenario over the no screening scenario. *EV* effect value, *horizontal line* represents the relative difference in lung cancer deaths with low-dose CT screening over no screening (the higher the EV, the higher the screening benefits), and *vertical dash line* indicates the location of estimated average EV, *prev* lung cancer prevalence in the screened cohort, *CTse* sensitivity of low-dose CT, *CTerl* proportion of early-stage cancers among lung cancers detected with low-dose CT, *srv_Er* survival possibility of patients with resected early-stage lung cancers, *NSerl* proportion of early-stage cancers among lung cancers detected with no screening, *CTidl* proportion of indolent cancers among lung cancers detected with low-dose CT, *fpMt* death possibility due to false diagnosis and invasive treatment, *srv_Ne* survival possibility of individuals with resected non-early-stage lung cancer, *trt_Er* acceptance rate of surgery for early-stage lung cancers, *CTsp* specificity of low-dose CT, *trt_Ne* acceptance rate of surgery for non-early-stage lung cancers. *Asterisk* the proportion of difference squared between low and high EV for each variable of the sum of differences squared for all variables. The *plus sign* denotes that the higher the variable value, the greater the reduction in lung cancer deaths with low-dose CT screening over no screening, and the *minus sign* denotes that the higher the variable value, the smaller the reduction in lung cancer deaths with low-dose CT screening over no screening

For the secondary outcome measures (not shown in figures), the factor that most influenced the number of false diagnosis was specificity of low-dose CT (negatively contributing 99.9% to variation in increased false diagnoses); lung cancer prevalence had a tiny negative influence (0.01%). Three factors were related to number of deaths due to false diagnosis with low-dose CT screening, namely, death possibility due to false diagnosis (93.0%, positive), low-dose CT specificity (7.0%, negative), and lung cancer prevalence (0.01%, negative). The factor that most influenced DALY was lung cancer prevalence (58.7%), followed by low-dose CT sensitivity (13.5%), low-dose CT specificity (11.0%), and proportion of early-stage cancers among lung cancers detected with low-dose CT (10.0%; all positive). Notably, a threshold of QALY was detected in lung cancer prevalence (436 per 100,000); the gain of QALY in low-dose CT screening over no screening would diminish if screening was performed among populations with a low prevalence of lung cancer.

Worst and optimal case analysis {#Sec13}
-------------------------------

Considering the possible ranges of all influential factors, reductions in lung cancer deaths with low-dose CT screening over no screening were 281 versus 297 (16 absolute reduction, 5.4% relative reduction) in the worst case and 428 versus 716 (288, 40.2% reduction) in the optimal case, and those over chest X-ray screening were 281 versus 270 (−11, −4.1% reduction) in the worst case and 428 versus 669 (241, 36.0% reduction) in the optimal case.

Influence of age criteria {#Sec14}
-------------------------

The influences of upper and lower age limits on prevalence of lung cancer in the screened cohort and on differences in numbers of lung cancer deaths between the three scenarios are shown in Table [3](#Tab3){ref-type="table"}. Relative to no screening, more than 200 fewer lung cancer deaths (24.5% relative reduction) could be achieved by setting the age criteria for low-dose CT screening at 55--75, 55--80, 60--70, 60--75, or 60--80 years. Similarly, these intervals for age criteria could lead to more than 130 fewer deaths (17.5% relative reduction) with low-dose CT screening over chest X-ray screening. However, some of these age intervals covered relatively small portions of the total lung cancer patients among the whole population of 45--80 years old, e.g., only 32.9% and 47.3% of patients with lung cancer would be covered if age criteria of 60--70 and 60--75 years were adopted, respectively. The age interval of 50--75 years currently recommended by the Chinese expert consensus for lung cancer screening \[[@CR20]\] covered 76.0% of all lung cancer patients aged 45--80 years, but the reduction in lung cancer deaths with low-dose CT screening was relatively low, 109 (17.4%) and 164 (24.3%), respectively, as compared with chest X-ray screening and no screening.Table 3Prevalence of lung cancer among 100,000 smokers and predicted lung cancer deaths in low-dose CT, chest X-ray, and no screening scenarios with different age inclusion criteriaAge interval (years)Lung cancer prevalence (per 100,000)Target coverage (%)^a^Lung cancer deaths (cases)Death reduction \[cases (%)\]Low-dose CTChest X-rayNo screeningLow-dose CT over chest X-rayLow-dose CT over no screening45--70589.270.234641745471 (17.0)108 (23.8)45--75675.484.739547752182 (17.2)126 (24.2)45--80766.6100.044854159193 (17.2)143 (24.2)50--70777.061.645454959995 (17.3)145 (24.2)50--75890.076.0519628686109 (17.4)167 (24.3)50--801009.491.3588712778124 (17.4)190 (24.4)55--70967.849.5564683746119 (17.4)182 (24.4)55--751115.663.9649787860138 (17.5)211 (24.5)55--801270.479.3738896980158 (17.6)242 (24.7)60--701263.032.9734891974157 (17.6)240 (24.6)60--751469.247.385210361133184 (17.8)281 (24.8)60--801680.262.797411851296211 (17.8)322 (24.8)^a^Proportion of lung cancer patients within the listed age interval among all lung cancer patients aged 45--80 years in urban China

Influence of smoking and sex criteria {#Sec15}
-------------------------------------

Figure [3](#Fig3){ref-type="fig"} shows that when not restricted to smokers, the reduction in lung cancer deaths with low-dose CT screening over chest X-ray screening and no screening increased in parallel with the proportion of smokers in the screened cohort, both among men and women. For example, compared with no screening, the relative reduction in lung cancer deaths among men undergoing low-dose CT screening increased from 23.2% for non-smokers to 24.2% for smokers, and the absolute screening benefit doubled from 69 to 143 fewer deaths. Similarly, the absolute benefit gained by low-dose CT screening also doubled compared with chest X-ray screening (from 45 to 93 fewer deaths) for men. Notably, among women the relative reduction in lung cancer deaths with low-dose CT screening was as great as that for men when screening 100% smokers (24.2% over no screening and 17.2% over chest X-ray screening), and the absolute reduction in lung cancer deaths with low-dose CT screening almost tripled both compared with no screening (from 49 in non-smokers to 143 in smokers) and chest X-ray screening (from 32 to 93).Fig. 3Reductions in lung cancer deaths with low-dose CT screening over chest X-ray screening and no screening among men and women of 45--80 years old with different proportions of smokers. *Bars* represent absolute reduction in deaths; *dotted lines* represent relative reduction in deaths. *Red* low-dose CT over chest X-ray screening for men, *yellow* low-dose CT over chest X-ray screening for women, *blue* low-dose CT over no screening for men, *green* low-dose CT over no screening for women. *Asterisk* lung cancer prevalence among the screened population, per 100,000

Discussion {#Sec16}
==========

This study evaluated the outcomes of lung cancer screening in China, including the influences of several factors on screening effects. According to the base-case analysis of 100,000 urban smokers aged 45--80 years, low-dose CT screening decreased lung cancer deaths by 24.2% over no screening and by 17.2% over chest X-ray screening. There were fewer deaths even in the worst case analysis (lung cancer deaths of 245 vs 269 for low-dose CT screening and no screening, respectively; 8.9% relative reduction), and the reduction was as high as 43.6% (lung cancer deaths of 364 vs 645 in low-dose CT screening and no screening, respectively) in an optimal situation. Thus, in terms of mortality outcome, our findings indicate that screening old smokers in urban China with low-dose CT would reduce lung cancer deaths. However, the effect of low-dose CT screening on lung cancer death reduction was inferior to that of chest X-ray screening in the worst situation (lung cancer deaths of 281 vs 270 for low-dose CT and chest X-ray screenings, respectively; −4.1% relative reduction). On average, low-dose CT screening resulted in more than three-fold false diagnoses and even deaths due to false diagnosis and over-treatment. Additionally, the gain in QALYs with low-dose CT screening (250 years over no screening and 147 years over chest X-ray screening) was not as pronounced as that for mortality. Thus, better screening strategies are required to optimize the outcomes of low-dose CT screening.

Being a country with a large lung cancer burden (with more than 3,500,000 new cases and more than 2,000,000 fatal cases each year \[[@CR37]\]), China has a considerable interest in the detection of early-stage lung cancer and prevention of lung cancer deaths via screening \[[@CR16], [@CR17]\]. Several studies have published preliminary results for the comparative ability of low-dose CT screening over chest X-ray screening to detect lung cancer and for other screening variables such as screening-detected cancer stage, pathological, and individual characteristics \[[@CR16], [@CR38]\]. In 2010, a demonstration program was initiated at three centers to test the feasibility of conducting population-based screening \[[@CR39]\]. Two years later, the government incorporated urban lung cancer screening into a key national public health program \[[@CR16]\]. Since 2013, approximately 8000 Beijing citizens have been screened in another program for 3 years using low-dose CT to optimize the screening protocol \[[@CR16]\]. Most studies have reported rates of detection, early diagnosis, and early treatment as the main outcomes; however, none have yet reported the endpoint of lung cancer mortality, both because it takes so long to obtain this important but time-consuming endpoint of screening and because a great many participants are needed to identify mortality differences at a low cancer prevalence. Thus, this analysis of currently available domestic data can provide information to the current screening practice before mortality outcome studies are available in China (which will not be very soon). The failure of small trials in Europe to detect any reduction in mortality has usually been attributed to insufficient in subject number (fewer than 2000 in low-dose CT arms) \[[@CR7]--[@CR9]\]. Only the statistically powered NLST study, with a sample size of 53,454, has detected a 20% mortality reduction with low-dose CT screening over chest X-ray screening \[[@CR5]\], which was why we simulated 100,000 participants to obtain robust results. The relatively smaller reduction in lung cancer deaths of 17.2% with low-dose CT screening over chest X-ray screening in the present study compared with the 20% in the NLST may be attributable to differences in enrollment criteria \[[@CR40]\] (such as smokers in the present study and heavy smokers in the NLST), other population characteristics, and quality of healthcare services.

In the present study, sensitivity analysis showed that the prevalence of lung cancer in the screened cohort was the factor with the strongest influence on reduction in lung cancer deaths, indicating that the selection criteria for eligibility for lung cancer screening programs should be carefully and rigorously defined \[[@CR40]\]. Although higher upper age limits for screening eligibility were related with greater reduction in mortality, individuals aged 75 years and older are more vulnerable than younger persons to clinical interventions such as invasive diagnostic and treatment procedures and are at high risk of death from other diseases (such as cardiac arrest and stroke). Thus, screening among this old population potentially affects the actual benefit from screening and may lead to ethical issues. Conversely, enrolling young individuals in screening programs results in only small gains from the perspective of screening service providers. Thus, a balance between risk and gain should be sought when selecting the age range to be screened. We recommend a mid-range spread, say 55--75 years: this age range has a relatively high screening benefit (24.5% reduction in lung cancer deaths with low-dose CT screening over no screening) and provides a relatively high coverage of those likely to have lung cancer (63.9% of those aged 45--80 years). As to the smoking criteria, we found that reductions in lung cancer deaths increase in parallel with the proportion of smokers in both men and women in the smoking cohort. We therefore strongly recommend consideration of low-dose CT screening for lung cancer in regions with high tobacco smoking rates, whereas regions with limited investment in screening should primarily target smokers. Additionally, the reduction in lung cancer deaths was not quite pronounced in this study with the relaxed inclusion criteria. It is noteworthy that when the emphasis is on heavy smokers and other criteria for screening are imposed (such as those in the Chinese Consensus on Early Diagnosis of Primary Lung Cancer \[[@CR20]\]), a greater screening benefit can be expected compared with nonselective criteria \[[@CR40]\]. Considering the important contribution of lung cancer prevalence to screening benefit, a combination of other methods such as biomarkers to identify high-risk individuals would also likely to increase screening benefits \[[@CR41]\].

Regarding other factors that influenced screening effects, the sensitivity of low-dose CT had a relatively important positive influence on the reduction in lung cancer deaths; so was the proportion of early-stage cancer among lung cancers detected with low-dose CT screening, reinforcing the need to develop highly sensitive screening techniques \[[@CR42]\]. The positive relationship between survival possibility after early treatment of cancer and reduction in deaths emphasizes the need to improve the effectiveness of early treatment to achieve better prognoses and screening benefits. Given the effect of acceptance of treatment on outcomes, screening programs should also consider incorporating approaches to enhancing willingness and financial ability of patients with lung cancer to undergo recommended treatment, particularly in developing countries. Additionally, our findings indicate that survival rates of non-early-stage cancer patients have a very limited impact on mortality outcomes.

For individuals who do not have lung cancers, false positive results remain the most critical issue of low-dose CT screening \[[@CR43]--[@CR45]\]. This is reinforced by the higher numbers of false diagnoses and deaths due to false diagnosis with low-dose CT screening compared with chest X-ray screening in the present study. Because the specificity of low-dose CT directly influences such outcomes, further efforts should be put into increasing the discriminative ability of imaging techniques and their computer-aided diagnostic systems \[[@CR46]\], developing optimal diagnostic thresholds \[[@CR44], [@CR45]\], and employing other imaging techniques (such as positron emission tomography) \[[@CR47]\] or other non-imaging approaches (such as highly specific biomarkers) \[[@CR41], [@CR48], [@CR49]\]. Additionally, standardization of workflow for diagnosis and treatment, in addition to screening, is indispensable to eliminating unnecessary cost and morbidities associated with lung cancer screening programs \[[@CR50]\].

In our study, gains in QALYs of low-dose CT screening over chest X-ray screening and no screening were less impressive than reduction in lung cancer deaths. This was mainly because unscreened individuals with lung cancer can enjoy a higher quality of life during the symptom-free interval before diagnosis of their cancers, whereas individuals with false-positive diagnoses experience a decreased quality of life as a result of anxiety and unnecessary diagnosis or treatment. For example, in the base-case analysis, these two sources resulted in loss of 562 QALYs in the low-dose CT screening scenario than in the no screening scenario (counterbalanced primarily by the stage-shift benefit of 812 QALYs, which led to the final 250-year gain). Thus, close attention should also be paid to physiological reactions if we wish to provide participants in the low-dose CT screening scenario with better quality of life \[[@CR51]\].

Limitations remain in this study. First, the decision tree we used is a simplified representation of complex clinical paths and individuals' behaviors. For example, we dichotomized the distribution of cancer stages into early and non-early; full I--IV staging (especially with associated differences in survival) would have made the model more accurate. This was mainly because of lack of large domestic studies from which we could draw robust estimates of screening and clinical parameters. Additionally, the absence of transition possibilities in lung cancer stage among the extremely heterogeneous histological types of lung cancer prevented us from employing stage transition Markov models. Second, for the same reasons, we only considered baseline screening in this study, whereas some programs in China already adopted a baseline and annual repeat screening fashion \[[@CR52]\], in which higher proportion of early-stage lung cancers in repeat rounds could be expected. Thus, longitudinal screening parameters from such programs and their impact on mortality reduction are highly needed for further decision analyses. Third, although false diagnoses, missed diagnoses, and over-diagnoses of indolent cancers were considered, we did not consider complex issues such as passive smoking and competing risk from other diseases in old individuals, but left these for future studies. Finally, the lack of expenditure data at the national level and differences in costs of lung cancer treatment between different regions thus far prevents evaluation of the cost-effectiveness of lung cancer screening. Thus, the balance between input and yield requires further in-depth evaluation.

Conclusions {#Sec17}
===========

Mortality outcome derived from this decision analysis were in favor of conducting low-dose CT screening in urban China for early detection and treatment of lung cancer. However, for nationwide promotion in the future, further work should be done to optimize the effects of screening, minimize false positive diagnoses, and improve participants' actual quality of life, such as by developing selection criteria for screening that are more appropriate to Chinese participants, standardizing diagnostic and treatment methods, and adapting screening protocols according to availability of funding and other local conditions.
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